Gold (I)-Based Compounds and their Potential as Chemo- and Targeted- therapeutics for Renal and Breast Cancer
DIPC Seminars
- Speaker
-
Maria Contel, Brooklyn College, The City University of New York
- When
-
2019/08/08
14:00 - Place
- Donostia International Physics Center
- Add to calendar
-
iCal
Gold compounds are emerging as promising anticancer chemotherapeutics with a
gold(I) compound Auranofin (a thiolate containing the [AuPEt3]+ fragment)
being evaluated in clinical trials. Our group at Brooklyn College has reported
on the preparation of heterometallic complexes containing titanocenes [TiCp2]
or ruthenium(II) arene derivatives [RuCl2(p-cymene)(dppm)] and
gold(I)-phosphane or gold(I)-N-heterocyclic NHC-carbene fragments and their
potential as chemotherapeutics against renal or colorectal cancers (including
studies of their efficacy in vivo, pharmacokinetics, histopathology and
mechanisms). We will provide a brief overview on this topic. We are also
working on strategies for the delivery of metal-based drugs so that they can
be efficiently released at the specific tumor site to improve selectivity,
bioavailability and blood circulation times. We will report on delivery
vehicles for gold(I)-based cytotoxic agents (containing phosphanes and NHC-
carbene ligands) consisting on: a) “smart†peptide nanocarriers, and b)
antibodies such as trastuzumab. We will describe synthetic strategies to
obtain antibody-drug conjugates and to encapsulate gold compounds in MMP-9
responsive peptide-based nanocarriers. Results for cellular viability assays
in human renal and breast cancer cell lines and non-cancerous cell lines to
highlight the tumor targeting properties of these systems will be discussed.
Host: Luca Salassa